Advertisement

Topics

Celgene’s Multiple Sclerosis Pill Meets Primary Endpoint in First Late-Stage Clinical Trial

09:38 EST 17 Feb 2017 | Speciality Pharma Journal

SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) today announced that its phase III SUNBEAM trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR), compared to weekly interferon (IFN) β-1a (Avonex®). …

Original Article: Celgene’s Multiple Sclerosis Pill Meets Primary Endpoint in First Late-Stage Clinical Trial

NEXT ARTICLE

More From BioPortfolio on "Celgene’s Multiple Sclerosis Pill Meets Primary Endpoint in First Late-Stage Clinical Trial"

Quick Search
Advertisement
 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...